Wladimir Hogenhuis has been appointed chief operating officer of Novato, CA-based Ultragenyx Pharmaceutical (NASDAQ: [[ticker:RARE]]). Hogenhuis comes to the rare disease drug developer from GlaxoSmithKline (NYSE: [[ticker:GSK]]), where he was senior vice president and general manager, specialty franchise. In April, Ultragenyx won FDA approval for burosumab (Crysvita), a drug developed to treat the rare bone disease X-linked hypophosphatemia.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
